The emerging class of GLP-1 receptor agonist and GIP combined medications, including tirzepatide, semaglutide, and the relatively introduced retatrutide, offer promising improvements in the control. While https://mots-c-peptide094797.bloghins.com/64079/retatrutide-a-comparative-review